ArticleRisk management and healthcare policy2021
Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE.
Article in Risk management and healthcare policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.Oral oncology · 2026Pooled it
- The prognostic value of systemic inflammation response index in digestive system carcinomas: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Development and Validation of a Nomogram for Predicting Response to TACE Combined with Lenvatinib and Anti-PD-1 Therapy in Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Prognostic Significance of Complete Blood Counts-Derived Inflammatory Markers in Compensated Hepatocellular Carcinoma.Journal of inflammation research · 2026Article
- Exploratory evaluation of the systemic inflammatory response index and internally evaluated machine learning models for prognosis in acute pesticide poisoning.American journal of translational research · 2026Article
- The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- The Predictive Role of the Systemic Inflammation Response Index in the Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Multicenter Study.Healthcare (Basel, Switzerland) · 2025Article
- Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value.Current oncology (Toronto, Ont.) · 2025Observational
- Article
- Joint association of systemic inflammatory response index and sarcopenia with mortality among individuals with self-reported cancer.BMC cancer · 2025Article
- Association between the systemic inflammatory response index and acute ischemic stroke in young people.Frontiers in neurology · 2025Article
- Inflammatory markers as predictors of liver fibrosis in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease.Frontiers in endocrinology · 2025Article
- Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.International journal of molecular sciences · 2024Review
- Preoperative systemic inflammation response index: Clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy.Journal of the Chinese Medical Association : JCMA · 2024Article
- Combined Bone Mineral Density (BMD) and Monocyte-to-Lymphocyte Ratio (MLR) Predicts Recurrence and Prognosis in Hepatocellular Carcinoma Patients Following Liver Resection.Risk management and healthcare policy · 2024Article
- Immune Predictors of Response after BacillusCancers · 2023Review
- Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer.Cancer medicine · 2023Article
- Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection.Journal of inflammation research · 2023Article
- Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMounting evidence has shown that systemic inflammation response index (SIRI), a novel prognostic biomarker based on peripheral lymphocyte, neutrophil and monocyte counts, is associated with poor prognosis for several tumors. However, the prognostic value of SIRI in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is elusive. Herein, we aimed to evaluate the correlation between SIRI and clinical outcomes in these patients.
methodsA total of 194 consecutive patients who underwent TACE were included in this study. Patients were stratified into high and low SIRI groups based on the cut-off value using receiver operating characteristic (ROC) analysis. Independent risk factors for tumor response were analyzed using forward stepwise logistic regression. A one-to-one propensity score matching (PSM) was conducted to compare progression-free survival (PFS) and overall survival (OS) between low and high SIRI patients. The discriminatory power of the combination of number of tumors and SIRI in predicting initial TACE response was evaluated by ROC analysis.
resultsPatients were divided into high SIRI (> 0.88) and low SIRI (≤ 0.88) groups. High SIRI (p = 0.003) and more than three tumors (p = 0.002) were significantly related to poorer tumor response. Moreover, the low SIRI group had longer PFS and OS than the high SIRI group (both P < 0.05) before and after PSM. Combination of SIRI and number of tumors can improve the predictive ability to predict initial TACE response with an area under the curve (AUC) of 0.678.
conclusionPretreatment peripheral blood SIRI was found to be an independent predictor of tumor response and clinical outcomes in patients with HCC undergoing TACE. Patients with high SIRI may have a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.